Tag Archives: biotechnology news

Wegner Paper Probes Myriad Decisions Flaws

Prof. Hal Wegner goes for the jugular with his analysis of some of the flaws in the legal reasoning behind the holding in the recent AMC v. Myriad decision. [See my post of July 31st 2011 on the decision]. (Prof. … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

AMC v. Myriad – “Laws of Nature” Exception Does Not Include Isolated DNA

As noted in my last “flash” post, a divided three-judge Fed. Cir. panel (Judges Lourie, Bryson and Moore) issued an opinion holding that the isolated DNA sequences and the drug-screening method claimed by Myriad are patentable subject matter, not natural … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , | 2 Comments

Divided Panel Finds DNA Molecules Patentable – Cancer Screening Claims Too Abstract

Today a divided Fed. Cir. panel of Judges Lourie, Moore and Bryson – Lourie writing for the “majority” – reversed the district court judge, in AMP v. Myriad, holding that isolated DNA sequences are patent-eligible subject matter and not natural … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , | Leave a comment

Inequitable Conduct in Canada – Disarming the “Atomic Bomb”

This is a guest post from Brian W. Gray of Norton Rose. This week a significant decision for patent owners was released from our Canadian Federal Court of Appeal. A copy of the case is found at the end of … Continue reading

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , , , , , , , , , , | 1 Comment